Hyoung Jin Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyoung Jin Kim has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Yingji Jin
Laboratory of Virology, College of Pharmacy, Chung-Ang University, Seoul, South Korea
9 shared publicationsHyoung Jin Kim
Laboratory of Virology, College of Pharmacy, Chung‑Ang University, Dongjak‑Gu, Seoul 06974, Republic of Korea
7 shared publicationsMei Ling Xu
Laboratory of Virology, College of Pharmacy, Chung‑Ang University, Dongjak‑Gu, Seoul 06974, Republic of Korea
7 shared publicationsSeung Cheol Kim
Department of Obstetrics and Gynecology, Ewha Woman's University College of Medicine, Yangcheon‑Gu, Seoul 03760, Republic of Korea
7 shared publicationsWoong Ju
Department of Obstetrics and Gynecology, Ewha Woman's University College of Medicine, Yangcheon‑Gu, Seoul 03760, Republic of Korea
7 shared publicationsYun Hwan Kim
Department of Obstetrics and Gynecology, Ewha Woman's University College of Medicine, Yangcheon‑Gu, Seoul 03760, Republic of Korea
6 shared publications
Latest Publications
- Open Access
- 15 July 2020
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 30 (9) , 1297-1304
Serum Levels and Glycosylation Changes of Alpha-1-Acid Glycoprotein According to Severity of Breast Cancer in Korean Women
Jae Woong Choi, Ki-Ho Jeong, Ji Won You, Jun Woo Lee, Byung-In Moon, Hyoung Jin Kim and Hong-Jin Kim*. J. Microbiol. Biotechnol. -0001;0:. https://doi.org/10.4014/jmb.2006.06007
- 15 July 2020
- Published by Korean Society for Microbiology and Biotechnology in Journal of Microbiology and Biotechnology
- Vol. 30 (9) , 1297-1304
Open AccessSerum Levels and Glycosylation Changes of Alpha-1-Acid Glycoprotein According to Severity of Breast Cancer in Korean Women
Jae Woong Choi, Ki-Ho Jeong, Ji Won You, Jun Woo Lee, Byung-In Moon, Hyoung Jin Kim and Hong-Jin Kim*. J. Microbiol. Biotechnol. -0001;0:. https://doi.org/10.4014/jmb.2006.06007
- 1 May 2020
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 100, 49-57
Current status and future directions of fish vaccines employing virus-like particles
- 1 May 2020
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 100, 49-57
Current status and future directions of fish vaccines employing virus-like particles
- 27 August 2019
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 57 (9) , 821-827
IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation
Most commercialized virus-like particle (VLP) vaccines use aluminum salt as adjuvant, even though VLPs provoke adequate antibody responses without adjuvant. We do not have detailed knowledge of how adjuvant affects the profile of anti-VLP antibodies. Meanwhile, there is evidence that differences between vaccination protocols influence the glycosylation of antibodies, which may alter their effector functions. In the present study a murine model was used to investigate the effects of dosing schedule and adjuvant on the antibody profiles and glycosylation levels of antigen-specific antibody responses to human papillomavirus type 16 L1 (HPV16 L1) VLPs. Mice received subcutaneously 2,000 ng of antigen divided into 4 or 7 doses. The HPV16 L1 VLPs elicited > 4 log10 anti-HPV16 L1 IgG titers without adjuvant, and aluminum hydroxide as adjuvant increased IgG titers 1.3- to 4-fold and reduced the anti-HPV16 L1 IgG2a / anti-HPV16 L1 IgG1 ratio value (use of aluminum hydroxide reduced the ratio of the IgG2a). Immunization with HPV16 L1 VLPs in combination with Freund’s adjuvant enhanced IgG titers 5- to 12-fold. Seven-dose immunization markedly increased anti-HPV16 L1 IgM titers compared to four-dose immunization, as well as increasing the proportion of glycosylated antibodies. Our results suggest that antibody glycosylation can be controlled immunologically, and IgG and IgM profiles and glycosylation profiles of the vaccine-induced antibodies can be used as indicators reflecting the vaccine characteristics. These results indicate that the HPV16 L1 VLP dosing schedule can affect the quality of antigen-specific antibody responses. We suggest that dosing schedules should be noted in vaccination protocols for VLP-based vaccines.
- 27 August 2019
- Published by The Microbiological Society of Korea in Journal of Microbiology
- Vol. 57 (9) , 821-827
IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation
Most commercialized virus-like particle (VLP) vaccines use aluminum salt as adjuvant, even though VLPs provoke adequate antibody responses without adjuvant. We do not have detailed knowledge of how adjuvant affects the profile of anti-VLP antibodies. Meanwhile, there is evidence that differences between vaccination protocols influence the glycosylation of antibodies, which may alter their effector functions. In the present study a murine model was used to investigate the effects of dosing schedule and adjuvant on the antibody profiles and glycosylation levels of antigen-specific antibody responses to human papillomavirus type 16 L1 (HPV16 L1) VLPs. Mice received subcutaneously 2,000 ng of antigen divided into 4 or 7 doses. The HPV16 L1 VLPs elicited > 4 log10 anti-HPV16 L1 IgG titers without adjuvant, and aluminum hydroxide as adjuvant increased IgG titers 1.3- to 4-fold and reduced the anti-HPV16 L1 IgG2a / anti-HPV16 L1 IgG1 ratio value (use of aluminum hydroxide reduced the ratio of the IgG2a). Immunization with HPV16 L1 VLPs in combination with Freund’s adjuvant enhanced IgG titers 5- to 12-fold. Seven-dose immunization markedly increased anti-HPV16 L1 IgM titers compared to four-dose immunization, as well as increasing the proportion of glycosylated antibodies. Our results suggest that antibody glycosylation can be controlled immunologically, and IgG and IgM profiles and glycosylation profiles of the vaccine-induced antibodies can be used as indicators reflecting the vaccine characteristics. These results indicate that the HPV16 L1 VLP dosing schedule can affect the quality of antigen-specific antibody responses. We suggest that dosing schedules should be noted in vaccination protocols for VLP-based vaccines.
- Open Access
- 6 May 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (1) , 255-264
Serum anti‑GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening
Recent studies have indicated that a certain level of autoantibodies may be essential for maintaining good health as well as preventing cancer development, and that the levels of serum autoantibodies can decline during malignant progression. The aim of the present study was to identify such an autoantibody‑based biomarker for screening cervical lesions. An autoantigen reactive with healthy female sera was detected in the cytosolic fraction of HeLa cells, a cervical cancer cell line, and identified. Serum immunoglobulin (Ig)‑G and IgM levels against the purified autoantigen in normal, cervical intraepithelial neoplasias (CINs) I, II and III, and cervical cancer were compared using ELISAs. The autoantigen in HeLa cells was identified to be GAPDH. The serum levels of anti‑HeLa‑GAPDH IgG decreased with increasing severity of cervical lesions, and similar decreases in IgM levels were revealed. Notably, the anti‑HeLa‑GAPDH IgG level was discovered to discriminate cervical cancer from normal samples with 80.0% sensitivity and 96.6% specificity. The serum anti‑HeLa‑GAPDH autoantibody level, as a single parameter, is a promising serum biomarker for screening cervical lesions.
- 6 May 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (1) , 255-264
Open AccessSerum anti‑GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening
Recent studies have indicated that a certain level of autoantibodies may be essential for maintaining good health as well as preventing cancer development, and that the levels of serum autoantibodies can decline during malignant progression. The aim of the present study was to identify such an autoantibody‑based biomarker for screening cervical lesions. An autoantigen reactive with healthy female sera was detected in the cytosolic fraction of HeLa cells, a cervical cancer cell line, and identified. Serum immunoglobulin (Ig)‑G and IgM levels against the purified autoantigen in normal, cervical intraepithelial neoplasias (CINs) I, II and III, and cervical cancer were compared using ELISAs. The autoantigen in HeLa cells was identified to be GAPDH. The serum levels of anti‑HeLa‑GAPDH IgG decreased with increasing severity of cervical lesions, and similar decreases in IgM levels were revealed. Notably, the anti‑HeLa‑GAPDH IgG level was discovered to discriminate cervical cancer from normal samples with 80.0% sensitivity and 96.6% specificity. The serum anti‑HeLa‑GAPDH autoantibody level, as a single parameter, is a promising serum biomarker for screening cervical lesions.
- Open Access
- 23 October 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (11) , 5655-5664
Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer
Sero‐epidemiological studies of human papillomavirus (HPV) have been undertaken over the last two decades. In this study, the prevalences of nine serum antibodies (anti‐E6, E7 and L1 antibodies of HPV types 16, 18, and 58) were evaluated in normal (control) Korean women and women with cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III, and cervical cancer. The frequencies of all types of anti‐HPV antibodies were higher in the CIN stages and cervical cancer than in normal women, and those of anti‐HPV16 E6 and E7, anti‐HPV18 E6 and E7, and anti‐HPV58 E7 antibodies were higher in the cervical cancer group than in the CIN stages. The frequencies of antibodies against HPV16, 18, and 58 E7 tended to increase with increasing severity of cervical lesions. However, there were few differences in the frequencies of antibodies against the L1 antigens of HPV16, 18 and 58 in cervical cancer versus CIN stages. The anti‐HPV antibodies were detected in 26.5% of normal, 46.3% of CIN I, 62.5% of CIN II, 51.6% of CIN III, and 75% of cancers when any of the nine antigens was used as a criterion. Correlations between HPV DNA positivity and seropositivity for anti‐HPV E6, E7, or L1 antibodies were found only in HPV16 DNA‐positive cervical cancers for anti‐HPV16 E6 and L1 antibodies. In addition, strong positive correlations in seropositivity were found between anti‐HPV16 E7 and anti‐HPV58 E7 antibodies, and between anti‐HPV18 E6 and anti‐HPV58 E6 antibodies. These findings should advance global profiling of the seroprevalences of antibodies against HPV antigens.
- 23 October 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (11) , 5655-5664
Open AccessProfiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer
Sero‐epidemiological studies of human papillomavirus (HPV) have been undertaken over the last two decades. In this study, the prevalences of nine serum antibodies (anti‐E6, E7 and L1 antibodies of HPV types 16, 18, and 58) were evaluated in normal (control) Korean women and women with cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III, and cervical cancer. The frequencies of all types of anti‐HPV antibodies were higher in the CIN stages and cervical cancer than in normal women, and those of anti‐HPV16 E6 and E7, anti‐HPV18 E6 and E7, and anti‐HPV58 E7 antibodies were higher in the cervical cancer group than in the CIN stages. The frequencies of antibodies against HPV16, 18, and 58 E7 tended to increase with increasing severity of cervical lesions. However, there were few differences in the frequencies of antibodies against the L1 antigens of HPV16, 18 and 58 in cervical cancer versus CIN stages. The anti‐HPV antibodies were detected in 26.5% of normal, 46.3% of CIN I, 62.5% of CIN II, 51.6% of CIN III, and 75% of cancers when any of the nine antigens was used as a criterion. Correlations between HPV DNA positivity and seropositivity for anti‐HPV E6, E7, or L1 antibodies were found only in HPV16 DNA‐positive cervical cancers for anti‐HPV16 E6 and L1 antibodies. In addition, strong positive correlations in seropositivity were found between anti‐HPV16 E7 and anti‐HPV58 E7 antibodies, and between anti‐HPV18 E6 and anti‐HPV58 E6 antibodies. These findings should advance global profiling of the seroprevalences of antibodies against HPV antigens.
- Open Access
- 10 May 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (1) , 145-154
Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera
Elevated serum CA15‑3 assessed by enzyme‑linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15‑3, which targets the peptide backbone of CA15‑3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody‑lectin sandwich assay detecting glycosylation of CA15‑3 in patients with breast cancer. Ιmmobilized anti‑CA15‑3 monoclonal antibody captures CA15‑3 in serum, and glycosylation of the CA15‑3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high‑mannose N‑glycans. ConA provided the best signal for detecting serum CA15‑3 among 9 types of lectin, Since CA15‑3 is a heavily glycosylated protein, detecting the glycosylation of CA15‑3 should be a much more sensitive way to assess CA15‑3 than the current ELISA method. Linear responses were obtained in the anti‑CA15‑3 antibody‑ConA sandwich assay when sera were diluted up to 2000‑fold. This dilution factor is comparable with that of the current ELISA system which allows 50‑ to 100‑fold serum dilutions. The glycosylation level of CA15‑3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody‑lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.
- 10 May 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (1) , 145-154
Open AccessUse of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera
Elevated serum CA15‑3 assessed by enzyme‑linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15‑3, which targets the peptide backbone of CA15‑3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody‑lectin sandwich assay detecting glycosylation of CA15‑3 in patients with breast cancer. Ιmmobilized anti‑CA15‑3 monoclonal antibody captures CA15‑3 in serum, and glycosylation of the CA15‑3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high‑mannose N‑glycans. ConA provided the best signal for detecting serum CA15‑3 among 9 types of lectin, Since CA15‑3 is a heavily glycosylated protein, detecting the glycosylation of CA15‑3 should be a much more sensitive way to assess CA15‑3 than the current ELISA method. Linear responses were obtained in the anti‑CA15‑3 antibody‑ConA sandwich assay when sera were diluted up to 2000‑fold. This dilution factor is comparable with that of the current ELISA system which allows 50‑ to 100‑fold serum dilutions. The glycosylation level of CA15‑3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody‑lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.
- 10 April 2018
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 41 (5) , 544-553
Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells
Insect and yeast cells are considered the expression systems of choice for producing virus-like particles (VLPs), and numerous types of VLPs have been produced in these systems. However, previous studies were restricted to identifying the characteristics of individual VLP preparations. No direct comparison of the structures and immunogenic properties of insect and yeast-derived VLPs has so far been made. In the present study, the size distribution and immunogenic properties of human papillomavirus type 16 (HPV16) L1 VLPs produced in Spodoptera frugipedra-9 insect cells and Saccharomyces cerevisiae were compared. The insect cell-derived VLPs were larger than the yeast ones (P < 0.0001), with median sizes of 34 and 26 nm, respectively. In addition, the insect-derived VLPs appeared to be more diverse in size than the yeast-derived VLPs. Immunization of mice with 30 ng per dose of VLPs elicited 2.7- and 2.4-fold higher anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers than immunization with the same amounts of the yeast-derived VLPs after the 4th immunizations, respectively. Our results suggest that the choice of expression system critically affects the particle size and immunogenic property of HPV16 L1 VLPs.
- 10 April 2018
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 41 (5) , 544-553
Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells
Insect and yeast cells are considered the expression systems of choice for producing virus-like particles (VLPs), and numerous types of VLPs have been produced in these systems. However, previous studies were restricted to identifying the characteristics of individual VLP preparations. No direct comparison of the structures and immunogenic properties of insect and yeast-derived VLPs has so far been made. In the present study, the size distribution and immunogenic properties of human papillomavirus type 16 (HPV16) L1 VLPs produced in Spodoptera frugipedra-9 insect cells and Saccharomyces cerevisiae were compared. The insect cell-derived VLPs were larger than the yeast ones (P < 0.0001), with median sizes of 34 and 26 nm, respectively. In addition, the insect-derived VLPs appeared to be more diverse in size than the yeast-derived VLPs. Immunization of mice with 30 ng per dose of VLPs elicited 2.7- and 2.4-fold higher anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers than immunization with the same amounts of the yeast-derived VLPs after the 4th immunizations, respectively. Our results suggest that the choice of expression system critically affects the particle size and immunogenic property of HPV16 L1 VLPs.
- 28 February 2018
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 41 (4) , 438-449
Use of protein-based biomarkers of exfoliated cervical cells for primary screening of cervical cancer
There has been no attempt to apply protein-based markers of exfoliated cervical cells (ECCs) for primary screening of cervical cancer. In the present study, the levels of six tumor-associated protein [TAPs: Sialyl Lewis A (SLeA), Cancer Antigen 15-3 (CA 15-3), p53, heat shock protein (Hsp)70, Hsp27 and squamous cervical carcinoma antigen (SCCA)]and of two human papillomavirus (HPV) viral proteins (HPV16 E7 and HPV16 L1) of ECCs lysates were evaluated by enzyme-linked immunosorbent assays (ELISAs).The wells of 96-well plates were coated with the ECCs lysates from normal, cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III and cancer groups, and candidate proteins were detected by relevant antibodies. SLeA level decreased with increasing severity of lesions, whereas the levels of other candidate proteins increased. SLeA, HPV16 L1 and p53 levels appeared more useful for detecting cervical lesions than the other candidates. The combination of ELISA-SLeA and ELISA-HPV16 L1 could efficiently detect cervical lesions from normal. The combination of ELISA-SLeA and ELISA-p53 could powerfully discriminate cancer from normal with 91.3% sensitivity and 96.7% specificity. The protein levels of ECCs have great potential as biomarkers for primary screening of cervical cancer.
- 28 February 2018
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 41 (4) , 438-449
Use of protein-based biomarkers of exfoliated cervical cells for primary screening of cervical cancer
There has been no attempt to apply protein-based markers of exfoliated cervical cells (ECCs) for primary screening of cervical cancer. In the present study, the levels of six tumor-associated protein [TAPs: Sialyl Lewis A (SLeA), Cancer Antigen 15-3 (CA 15-3), p53, heat shock protein (Hsp)70, Hsp27 and squamous cervical carcinoma antigen (SCCA)]and of two human papillomavirus (HPV) viral proteins (HPV16 E7 and HPV16 L1) of ECCs lysates were evaluated by enzyme-linked immunosorbent assays (ELISAs).The wells of 96-well plates were coated with the ECCs lysates from normal, cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III and cancer groups, and candidate proteins were detected by relevant antibodies. SLeA level decreased with increasing severity of lesions, whereas the levels of other candidate proteins increased. SLeA, HPV16 L1 and p53 levels appeared more useful for detecting cervical lesions than the other candidates. The combination of ELISA-SLeA and ELISA-HPV16 L1 could efficiently detect cervical lesions from normal. The combination of ELISA-SLeA and ELISA-p53 could powerfully discriminate cancer from normal with 91.3% sensitivity and 96.7% specificity. The protein levels of ECCs have great potential as biomarkers for primary screening of cervical cancer.
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (28) , e186
Surgical Strategy for T2 Gallbladder Cancer: Nationwide Multicenter Survey in Korea
Lee SE, et al. J Korean Med Sci. 2018 May;33(28):e186. https://doi.org/10.3346/jkms.2018.33.e186
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (28) , e186
Open AccessSurgical Strategy for T2 Gallbladder Cancer: Nationwide Multicenter Survey in Korea
Lee SE, et al. J Korean Med Sci. 2018 May;33(28):e186. https://doi.org/10.3346/jkms.2018.33.e186
- 1 January 2018
- Published by Elsevier in Biologicals
- Vol. 51, 25-31
Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles
- 1 January 2018
- Published by Elsevier in Biologicals
- Vol. 51, 25-31
Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles